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Abstract
Atorvastatin (a 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor) is a widely used cholesterol-lowering
drug, which is recognized for its potential hepatotoxicity. This study investigated in vitro effects of this agent on
hepatic tissue respiration, ATP content, caspase activity, urea synthesis and histology. Liver fragments from Taylor
Outbred and C57Bl/6 mice were incubated at 37°C in Krebs-Henseleit buffer continuously gassed with 95% O2: 5%
CO2 in the presence and absence of atorvastatin. Phosphorescence O2 analyzer that measured dissolved [O2] as a
function of time was used to monitor cellular mitochondrial O2 consumption. The caspase-3 substrate N-acetyl-asp-
glu-val-asp-7-amino-4-methylcoumarin was used to monitor caspase activity. The rates of hepatocyte respiration
(μM O2 min-1 mg-1) in untreated samples were 0.15 ± 0.07 (n = 31). The corresponding rates for samples treated
with 50 nM (therapeutic concentration), 150 nM or 1.0 μM atorvastatin for ≤13 h were 0.13 ± 0.05 (n = 19), p = 0.521.
The contents of hepatocyte ATP (pmol-1 mg-1) in untreated samples were 40.3 ± 14.0 and in samples treated with
1.0 μM atorvastatin for ≤4.5 h were 48.7 ± 23.9 (p = 0.7754). The concentrations of urea (mg/dL mg-1, produced over
50 min) for untreated samples were 0.061 ± 0.020 (n = 6) and for samples treated with 1.0 μM atorvastatin for ≤6 h
were 0.072 ± 0.022 (n = 6), p = 0.3866. Steadily, hepatocyte caspase activity and histology were unaffected by
treatments with up to 1.0 μM atorvastatin for ≤6 h. Thus, the studied murine model showed preserved hepatocyte
function and structure in the presence of high concentrations of atorvastatin.
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Background
Statins, 3-hydroxy-3-methylglutaryl coenzyme-A reductase in-
hibitors, are the most effective class of drugs that treat hyper-
cholesterolemia. These agents reduce hepatocyte cholesterol,
which results in up-regulation of the low-density lipoprotein
(LDL) receptors and increased clearance of LDL-cholesterol
from the plasma. Atorvastatin, (3R,5R)-7-[2-(4-fluorophenyl)-
3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-
1-yl]-3,5-dihydroxyheptanoic acid, is considered “best-in-class”
for meeting the recommended treatment guidelines [1].
Elevations of liver alanine and aspartate aminotransfer-
ases (ALT and AST) are well-recognized adverse events
of atorvastatin [2-4], occurring in about 0.5% of patients,
usually in the first few months of therapy [5,6]. Since
other lipid-lowering compounds also increase liver ami-
notransferases, it has been debated whether statin-
associated elevated transaminases are due to hepatotox-
icity or a reaction to reduced cholesterol [7]. More re-
cent studies have shown statins are well tolerated by
patients with primary biliary cirrhosis, hepatitis C and
non-alcoholic steatohepatitis [8-10]. Furthermore, a few
short-term studies showed statins improved hepatic in-
flammation in patients with non-alcoholic fatty liver dis-
ease [11]. In a prospective, double blind trial of 326
patients with chronic liver disease, fewer patients in the
pravastatin group had elevations in ALT compared to
placebo (7.5% vs. 12.5%, p = 0.13) [12]. The recent post
hoc analysis of safety of atorvastatin in the Greek Ator-
vastatin and Coronary Heart Disease Evaluation
(GREACE) study showed atorvastatin significantly ame-
liorated elevations of AST and ALT [13]. Other reports
in humans and animals showed hepatotoxicities of
statins [14], including caspase activation (apoptosis) and
induction of mitochondrial disturbances [15]. These tox-
icities could stem from confounding factors, such
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idiosyncratic reactions, hypercholesterolemia, concomi-
tant medications and co-morbidities (e.g., diabetes
mellitus).
The term “cellular bioenergetics” implies the biochem-
ical processes involved in energy metabolism (energy
conversion or transformation), and the term “cellular
respiration” (mitochondrial O2 consumption) describes
the delivery of metabolites and O2 to the mitochondria,
the oxidation of reduced metabolic fuels with passage of
electrons to O2, and the synthesis of ATP. Impaired bio-
energetics or respiration entails interferences with any of
these processes.
Apoptosis describes the highly regulated mechanisms
responsible for cellular responses to injuries and adverse
biological signals. This process produces deleterious mor-
phological and biochemical changes, including mitochon-
drial disturbances that may lead to cell death [16].
Caspases, cysteine aspartate-directed proteases and mem-
bers of the interleukin-1β-converting enzyme (ICE), are
key executers of apoptosis. Intracellular caspase activity
can be monitored using the caspase-3 synthetic substrate
N-cetyl-asp-glu-val-asp-7-amino-(4-methyl- coumaryl-7-
amide) (Ac-DEVD-AMC). Caspase-3 is involved in prote-
olysis of proteins, including poly(ADP ribose) polymerase.
The enzyme cleaves at the C-terminal to Asp216 in the
asp-glu-val-asp sequence. This 4-amino-acid motif has
been utilized for the highly specific caspase-3 substrate
Ac-DEVD-AMC. Caspase-3 cleaves the tetrapeptide
between D and AMC, releasing the fluorogenic moiety 7-
amino-4-methylcoumarin (AMC). The latter can be sepa-
rated on HPLC and detected by fluorescence with a great
accuracy [17].
The primary aim of the study here was to investigate
the effects of atorvastatin on hepatocyte bioenergetics
and caspase activity. The described in vitro murine sys-
tem allowed accurate assessment of multiple hepatic bio-
markers as a function of time using murine liver tissue.
The results show liver tissue function and structure are




Atorvastatin was purchased from Selleck Chemicals
(Houston, TX, USA). Pd(II) complex of meso-tetra-(4-
sulfonatophenyl)-tetrabenzoporphyrin (Pd phosphor) was
purchased from Porphyrin Products (Logan, UT). A lyoph-
ilized powder of caspase inhibitor I [N-benzyloxycarbonyl-
val-ala-asp(O-methyl)-fluoromethylketone, zVAD-fmk,
m.w. = 467.5, a pan-caspase inhibitor] was purchased
from Calbiochem (La Jolla, CA). Ac-DEVD-AMC (N-
acetyl-asp-glu-val-asp-7- amino-4-methylcoumarin; m.
w. = 675.64; caspase-3 substrate) was purchased from
Axxora LLC (San Diego, CA). CompleteW protease
inhibitor cocktail was purchased from Roche Applied Sci-
ence (Indianapolis, IN). Glucose (anhydrous), endotoxin-
and fatty acid-free bovine serum albumin and remaining
reagents were bought from Sigma-Aldrich (St. Louis, MO).
The pan-caspase inhibitor (zVAD-fmk) solution (2.14 mM)
was made by dissolving 1.0 mg in 1.0 mL dimethyl sulfoxide
and stored at -20°C. Ac-DEVD-AMC solution (7.4 mM) was
made by dissolving 5.0 mg in 1.0 mL dimethyl sulfoxide and
stored at -20°C. Pd phosphor solution (2.5 mg/mL= 2 mM)
was prepared in dH2O and stored in aliquots at -20°C. NaCN
solution (1.0 M) was prepared in dH2O; the pH was adjusted
to ~7.0 with 12 N HCl and stored at -20°C. Glucose oxidase,
10 mg/mL in dH2O, was stored at -20°C. One tablet of
CompleteW protease inhibitor cocktail was dissolved in
1.0 mL Water-For-Injection and stored at -20°C.
Mice
Male Taylor Outbred (TO, age: 9-10 weeks, weight: 30-
35 g) and C57Bl/6 (age: 9-10 weeks, weight: 20-22 g)
mice were maintained at an animal facility that was in
compliance with NIH guidelines (http://grants.nih.gov/
grants/olaw/references/phspol.htm). The mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME).
All mice were housed in rooms maintained at 22°C with
~60% relative humidity and a 12-hr light/dark cycle. All
mice had ad libitum access to standard rodent chow and
filtered water. All protocols here received approval from
the Animal Ethics Committee-United Arab Emirates
University-College of Medicine and Health Sciences.
Liver tissue
Mice were anesthetized by sevoflurane inhalation (100
μL per 10 g body weight). Liver specimens (~20 to
30 mg) were collected using a 4-mm human skin biopsy
punch (Miltex GmbH, Germany) and immediately
immersed in 50 mL ice-cold modified Krebs-Henseleit
(KH) buffer (115 mM NaCl, 25 mM NaHCO3, 1.23 mM
NaH2PO4, 1.2 mM Na2SO4, 5.9 mM KCl, 1.0 mM
EDTA, 1.18 mM MgCl2, 10 mM glucose, and 0.5 μL/mL
CompleteW protease inhibitor cocktail, pH 7.5) continu-
ously gassed with 95% O2: 5% CO2 [18].
The samples were then incubated in vitro at 37°C in
50 mL in KH buffer (115 mM NaCl, 25 mM NaHCO3,
1.23 mM NaH2PO4, 1.2 mM Na2SO4, 5.9 mM KCl,
1.25 mM CaCl2, 1.18 mM MgCl2, and 10 mM glucose,
pH 7.5) supplemented with 0.5 μL/mL CompleteW pro-
tease inhibitor cocktail and continuously gassed with
95% O2: 5% CO2. For the O2 measurement, specimens
were placed in 1.0 mL KH buffer (air-saturated)
containing 0.5% fatty acids-free bovine albumin and
3 μM Pd phosphor. Specimens were also processed for
measuring caspase activity, urea synthesis and histology
as described below.
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Oxygen measurement
Phosphorescence oxygen analyzer was used to monitor O2
consumption by liver specimens [18,19]. O2 detection was
performed with the aid of Pd phosphor that had absorp-
tion maximum at 625 nm and phosphorescence max-
imum at 800 nm. Samples were exposed to light flashes
(600 per min) from a pulsed light-emitting diode array
with peak output at 625 nm (OTL630A-5-10-66-E, Opto
Technology, Inc., Wheeling, IL). Emitted phosphorescent
light was detected by a Hamamatsu photomultiplier tube
(928) after first passing it through a wide-band interfer-
ence filter centered at 800 nm. The amplified phosphores-
cence decay was digitized at 1.0 MHz by a 20-MHz A/D
converter (Computer Boards, Inc., Mansfield, MA).
A program was developed using Microsoft Visual Basic 6,
Microsoft Access Database 2007, and Universal Library com-
ponents (Universal Library for Measurements Computing
Devices; http://www.mccdaq.com/daq-software/universal-li-
brary.aspx). It allowed direct reading from the PCI-DAS
4020/12 I/O Board (PCI-DAS 4020/12 I/O Board; http://
www.mccdaq.com/pci-data-acquisition/PCI-DAS4020-12.
aspx). The pulse detection was accomplished by searching
for 10 phosphorescence intensities >1.0 volt (by default).
Peak detection was accomplished by searching for the
highest 10 data points of a pulse and choosing the data point
closest to the pulse decay curve [20].
The phosphorescence decay rate (1/τ) was character-
ized by a single exponential; I = Ae-t/τ, where I = Pd
phosphor phosphorescence intensity. The values of 1/τ
were linear with dissolved O2: 1/τ = 1/τ
o + kq[O2], where
1/τ = the phosphorescence decay rate in the presence of
O2, 1/τ
o = the phosphorescence decay rate in the absence
of O2, and kq = the second-order O2 quenching rate con-
stant in s-1 • μM-1.
Respiration was measured at 37°C in 1-mL sealed vials.
Mixing was with the aid of parylene-coated stirring bars.
In vials sealed from air, [O2] decreased linearly with
time, indicating the kinetics of mitochondrial O2 con-
sumption was zero-order. The rate of respiration (k, in
μM O2 min
-1) was thus the negative of the slope d[O2]/
dt. NaCN inhibited respiration, confirming O2 was con-
sumed in the mitochondrial respiratory chain.
The calibration reaction contained PBS with 3 μM Pd
phosphor, 0.5% fat-free albumin, 50 μg/mL glucose oxidase
and various concentrations of β-glucose. [O2] was calcu-
lated using, 1/τ = 1/τo + kq[O2] [21]. Rates of cellular respir-
ation were normalized per mg of liver tissue (i.e., expressed
as μMO2 consumed per min per mg liver tissue).
ATP content
Liver fragments were homogenized in ice-cold 2%
trichloroacetic acid for 2 min and neutralized with
100 mM Tris-acetate, 2 mM EDTA, pH 7.75. The super-
natant was collected by centrifugation (1000 × g at 4°C
for 5 min) and stored at -20°C until analysis. The pH of
samples was adjusted to 7.75 immediately before ATP
determination. ATP concentration was measured using
the Enliten ATP Assay System (Bioluminescence Detec-
tion Kit, Promega, Madison, WI). Briefly, 2.5 μL of the
acid-soluble supernatant was added to 25 μL of the
luciferin/luciferase reagent. The luminescence intensity
was measured at 25°C using Glomax Luminometer
(Promega, Madison, WI). The ATP standard curve was
linear from 10 pM to 100 nM (R2 >0.9999).
Intracellular caspase activity
Liver specimens were incubated at 37°C in oxygenated
KH buffer containing 37 μM Ac-DEVD-AMC with and
without 32 μM zVAD-fmk (final volume, 0.5 mL). The tis-
sue was then disrupted by vigorous homogenization and
10 passages through a 27-G needle. The Ac-DEVD-AMC
cleavage reaction was quenched with tissue disruption,
mainly because caspases became inactive due to dilution.
The supernatant was collected by centrifugation (16,300 g
for 90 min) through a Microcentrifuge Filter (nominal
molecular weight limit = 10,000 Dalton, Sigma©), sepa-
rated on HPLC, and analyzed for the free fluorogenic
AMC moiety. The elution time for AMC was about
5.0 min.
HPLC
The analysis was performed on a Waters 1525 reversed-
phase HPLC system (Spectra Lab Scientific Inc, Alexandria,
VA) that consisted of manual injector, pump and fluores-
cence detector. The excitation wavelength used was
380 nm and the emission wavelength 460 nm. Solvents A
and B were HPLC-grade CH3OH: dH2O (1:1; isocratic).
The Ultrasphere IP column (4.6 × 250 mm, Beckman) was
operated at 25°C at 1.0 mL/min. The run time was 20 min.
The injection volume was 50 μL.
Urea synthesis
Liver specimens were incubated at 37°C in 50 mL KH
buffer (continuously gassed with 95% O2: 5% CO2) with
and without 1.0 μM atorvastatin for up to 6 h. Speci-
mens were then removed from the incubation solution
every 60 min and placed in 1.0 mL KH buffer
supplemented with 10 mM NH4Cl and 2.5 mM orni-
thine. The reactions were allowed to continue at 37°C
for 50 min with continuous gassing as above. At the end
of the incubation period, the solutions were analyzed for
urea as described [22]. Blood urea nitrogen (BUN,
mmol/L) was measured using standard laboratory
methods with an LX20 multiple automated analyzer
(Beckman Coulter, CA, USA). For conversion, BUN
(mg/dL) = BUN (mmol/L) ÷ 0.357; Urea (mg/dL) = BUN
(mg/dL) × 2.14.
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Histology
Liver samples were fixed in 10% neutral formalin,
dehydrated in increasing concentrations of ethanol,
cleared with xylene and embedded in paraffin. Four-
micrometer sections were prepared from paraffin blocks
and stained with hematoxylin and eosin.
Statistical analysis
Data were analyzed using SPSS statistical package (version
19). The nonparametric test (2 independent variables)
Mann-Whitney was used to compare treated and un-
treated samples. Respiration rates (kc, in μM O2 min
-1
mg-1), cellular ATP content (pmol mg-1), AMC peak areas
(arbitrary unit mg-1) and urea (mg/dL per mg liver tissue)
for untreated samples were compared with those for
treated samples.
Results
Bioenergetics of liver tissue treated with atorvastatin
To assess the effects of atorvastatin on liver tissue bio-
energetics, specimens from ten Taylor Outbred (TO)
mice and three C57Bl/6 mice were incubated at 37°C
with 50 nM (therapeutic concentration; Maier et al.
[23]), 150 nM or 1.0 μM atorvastatin and analyzed for
cellular O2 consumption and ATP content as a function
of time. Results of representative experiments are shown
in Figure 1.
In Figure 1A-B, liver specimens from TO mice were in-
cubated at 37°C in 50 mL KH buffer (continuously gassed
with 95% O2: 5% CO2) with and without 150 nM atorva-
statin for up to 6 h. Samples were alternatively removed
from the incubation mixture and processed for O2
measurement at 37°C. The rate of respiration (k, μM O2
min-1) was set as the negative of the slope of [O2] vs. t.
The values of kc (μM O2 min
-1 mg-1; mean ± SD) for un-
treated samples were 0.18 ± 0.06 (n = 5, for t from 1.8 to
5.3 h) and for treated samples 0.18 ± 0.05 (n = 3, for t from
1.1 to 3.7 h), p = 0.9737.
Liver samples were also incubated as above with and
without 50 nM atorvastatin. The value of kc for untreated
tissue was 0.15 μMO2 min
-1 mg-1 (t = 1.4 h) and for treated
tissue 0.15 μM O2 min
-1 mg-1 (t = 2.2 h). In 10 independent
experiments involving incubations with 50 nM, 150 nM or
1.0 μM atorvastatin for up to 13 h, the rates of respiration
for untreated specimens were 0.15 ± 0.07 (n = 31 runs) and
for treated specimens 0.13 ± 0.05 (n = 19 runs), p = 0.521.
In C57Bl/6 strain, the value of kc for untreated tissue was
0.10 ± 0.03 (1.8 < t < 5.3 h, n = 5) and for tissue treated
with 1.0 μM atorvastatin 0.11 ± 0.04 (for t from 1.1 to 3.7 h,
n = 4). In another experiment, the value of kc for untreated
tissue was 0.12 ± 0.05 (for t from 1.3 to 5.9 h, n = 4) and
treated tissue 0.12 ± 0.04 (for t from 0.5 to 4.4 h, n = 3).
Thus, hepatocyte respiration was preserved in the presence
of high doses of atorvastatin for up to 13 h.
In Figure 1C-D, liver samples were incubated as above
with and without 1.0 μM atorvastatin for up to 6.5 h and
processed for measurements of cellular respiration and
ATP content. The results are plotted as a function of incuba-
tion time in Panel D. The values of kc for untreated samples
(for t from 0 to 5.3 h) were 0.17 ± 0.03 μM O2 min
-1 mg-1
and for treated samples (for t from 0 to 4.5 h) 0.16 ±
0.02 μM O2 min
-1 mg-1 (p= 0.3954). Cellular ATP at t= 0 h
was 181.1 ± 8.0 pmol mg-1. For untreated specimens, cellular
ATP (in pmol mg-1, measured in triplicates) at t= 1.3 h was
33.9 ± 1.7, at t= 2.0 h was 61.2 ± 1.4, at t= 3.5 h was 32.6 ±
1.4, and at t= 5.3 h was 33.4 ± 6.8. For treated specimens,
cellular ATP at t= 0.3 h was 66.5 ± 3.9, at t= 3.0 h was
58.0 ± 7.4 and at t= 4.5 h was 21.6 ± 6.1. Thus, the overall
ATP contents for untreated samples (for t from 1.3 to
5.3 h) were 40.3 ± 14.0 and for treated samples (for t from
0.3 to 4.5 h) 48.7 ± 23.9 (p = 0.7754). In another experi-
ment, ATP contents at 6 h for untreated tissue were 10.5 ±
1.0 (n = 4) and for treated tissue 16.6 ± 0.9 (n = 4). Thus,
hepatocyte ATP was highest immediately after tissue col-
lection (in vivo levels of hepatocyte bioenergetics) and de-
clined equally in the presence and absence of atorvastatin
(in vitro levels of hepatocyte bioenergetics).
Hepatocyte caspases in liver tissue treated with
atorvastatin
Representative experiments for hepatocyte caspase activ-
ity in TO (Panels A-B) and C57BL/6 (Panels C-D)
strains are shown in Figure 2. The samples were incu-
bated at 37°C with and without 1.0 μM atorvastatin for
6 h. The specimens were then incubated at 37°C with
37 μM Ac-DEVD-AMC in the presence and absence of
zVAD-fmk (32 μM). In untreated samples from the TO strain
(Panel A), the AMC peak area (arbitrary unit, reflecting
caspase activity) without zVAD was 1,627,780 mg-1 and with
zVAD was 121,952 mg-1 (93% inhibition). In treated samples
(Panel B), the AMC peak area without zVAD was
963,346 mg-1 and with zVAD was 152,144 mg-1 (84% inhib-
ition). In untreated samples from the C57BL/6 strain (Panel
C), the AMC peak area without zVAD was 1,988,712 mg-1
and with zVAD 125,667 mg-1 (94% inhibition). In treated
samples (Panel D), the AMC peak area without zVAD was
2,068,736 mg-1 and with zVAD 119,295 mg-1 (94% inhib-
ition). Thus, hepatocyte caspase activity at 6 h was similar in
untreated and treated samples.
Urea synthesis by liver tissue treated with atorvastatin
Liver specimens were incubated at 37°C in 50 ml KH
buffer (continuously gassed as above) with and without
1.0 μM atorvastatin for 6 hr. Every 60 min, specimens
(sum sample weight = 86.9 ± 5.9 mg) were removed from
the incubation solutions and placed in 1.0 mL KH buffer
supplemented with 10 mM NH4Cl and 2.5 mM orni-
thine. The solutions were then analyzed for urea at min
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50. The concentrations of urea (mg/dL per mg liver tis-
sue) for untreated and treated samples were not signifi-
cantly different (Table 1).
Histology
Representative micrographs of hematoxylin and eosin
stained sections of untreated tissue at 0 and 6 hr
and tissue treated with 1.0 μM atorvastatin at 6 hr
are shown in Figure 3. The incubation conditions
were as above. Liver architecture and cytology were
preserved in treated and untreated specimens. In-
flammation and cholestasis were absent.
Discussion
Asymptomatic increase in hepatic transaminases is most
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Figure 1 Atorvastatin neither alters hepatocyte respiration nor hepatocyte ATP content. Panels A-C: Cellular mitochondrial O2 consumption
with and without atorvastatin. Panels A-B, O2 runs with and without 150 nM atorvastatin. Panel C, O2 runs with and without 1.0 μM atorvastatin. Panel
D: Cellular ATP content and values of kc as a function of incubation time. Liver specimens from TO mice were incubated in vitro at 37°C in 50 mL KH
buffer (continuously gassed with 95% O2: 5% CO2) with and without 150 nM (A-B) or 1.0 μM (C-D) atorvastatin. Cellular O2 consumption and ATP
content were determined as a function of time; t = 0 corresponded to tissue collection. The lines in Panels A-C are linear fits (0.873 < R2 < 0.955). The
rate of respiration (k, μM O2 min-1) was set as the negative of the slope of [O2] vs. t. The values of kc (μM O2 min-1 mg-1) are shown at the bottom of
each run. The values of kc in Panel C and the cellular ATP content of the same experiment are plotted in Panel D. Eleven independent experiments
were done with the TO mice and 4 independent experiments were done with the C57Bl/6 mice. U, untreated; T, treated.
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about 0.5% of patients [1]. Other hepatocellular injuries,
such as cholestasis, immune hepatitis and fulminant
liver failure are also possibly linked to atorvastatin use
(Bhardwaj and Chalasani [7]; see also atorvastatin
product insert). The duration between exposure and
onset of toxicity varies, ranging from 12 hours to 52 -
weeks. The transaminase elevations, however, are fre-
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Figure 2 Atorvastatin does not induce hepatocyte caspases. Panel A, untreated liver specimens from TO mice. Panel B, atorvastatin-treated
liver specimens from TO mice. Panel C, untreated liver specimens from C57Bl/6 mice. Panel D, atorvastatin-treated liver specimens from C57Bl/6
mice. Representative experiments of liver specimens incubated in vitro at 37°C with (B and D) and without (A and C) 1.0 μM atorvastatin for 6 hr
are shown. At the end of incubation period, the samples (24.7 to 35.1 mg) were rinsed and incubated at 37°C in 1.0 mL oxygenated KH buffer
with and without 32 μM zVAD-fmk for 10 min. Ac-DEVD-AMC (37 μM) was then added and the incubation continued for 20 min. The tissues were
vigorously disrupted and the supernatants were separated on HPLC and analyzed for the AMC (Rt, ~5.0 min) and Ac-DEVD-AMC peaks
(Rt, ~2.5 min). Eleven independent experiments were done with the TO mice and 4 independent experiments were done with the C57Bl/6 mice.
Table 1 Urea synthesis (mg/dL mg-1, produced over
50 min) by liver tissue treated with atorvastatin
Untreated (n =6) Treated (n =6) P-value
0.061 ± 0.020 0.072 ± 0.022 0.3866
Liver specimens were incubated at 37°C in KH buffer with and without 1.0 μM
atorvastatin for 6 hr. Every 60 min, specimens were removed from the
incubation solutions and placed in 1.0 mL KH buffer supplemented with
10 mM NH4Cl and 2.5 mM ornithine. The solutions were then analyzed for
urea at min 50. The values are mean ± SD for hr 1 to 6.
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Oxygen consumption is sensitive to reduced cellular
metabolic fuels, as well as to mitochondrial derange-
ments. Cellular respiration is reduced in the presence of
nutrient depletion or electron transport chain deficits.
The rate of respiration, on the other hand, is enhanced
in the presence of proton leak (uncoupling oxidative
phosphorylation). As shown previously, measurements
of cellular mitochondrial oxygen consumption by the
phosphorescence oxygen analyzer are highly sensitive to
these cellular insults [17]. Moreover, liver architecture
and urea synthesis are typical biomarkers for assessing
hepatocyte injury [25].
Hepatotoxicities were evident in diabetic and hyper-
cholesterolemic rats treated with oral atorvastatin
(5 mg/kg daily) for two months [14]. Several reports also
described statin-induced mitochondrial toxicities (see
Dykens and Will [26]). More recently, impaired mito-
chondrial oxidative phosphorylation, membrane fluidity
and coenzyme Q (ubiquinone, a component of the mito-
chondrial respiratory chain) content were reported in
rats treated with 80 mg/kg atorvastatin for 4 weeks. The
authors suggested that impaired hepatocyte bioenerget-
ics may play a role in the development of statin-induced
hepatotoxicities [15].
Atorvastatin also exerts cytotoxic effects on human
hematopoietic tumors by promoting apoptosis through
the mitochondrial cell death pathway. Other potential
mechanisms involve altering the membrane localization of
small GTPases. Treatment with statin resulted in reduc-
tion of mitochondrial membrane potential and cytosolic
release of the activator of caspases Smac/DIABLO. As a
result, caspases 9, 3 and 8 were efficiently activated [27].
This study investigated whether atorvastatin impairs
hepatocyte cellular bioenergetics (respiration and ATP con-
tent). Strain-specific drug toxicities have been described
[28]. Therefore, our animal model always tests different
murine strains or a murine strain and a rat strain. The re-
sults clearly show preserved murine hepatocyte respiration
and ATP content following in vitro exposure to 1.0 μM
atorvastatin for several hours (Figure 1). This concentra-
tion is about 20-fold higher than therapeutic plasma levels.
Consistently, hepatocyte caspase activity (Figure 2) and
liver architecture (Figure 3) are preserved in the presence
of 1.0 μM atorvastatin and indeed inflammation and chole-
stasis were absent. Thus, in the studied murine hepatic
model, atorvastatin was not toxic. It is unknown, however,
whether a much longer exposure produces cytotoxicity
and will definitely be a venture for future research.
Cellular ATP was highest immediately after tissue col-
lection (reflecting in vivo levels of bioenergetics) and de-
clined subsequently to a new steady state (reflecting
in vitro levels of bioenergetics), Figure 1D. This assump-
tion is consistent with the preserved hepatocyte struc-
ture (Figure 3) and ultrastructure (data not shown)
following tissue collection. Along the same lines, about











Figure 3 Micrographs of hematoxylin and eosin-stained liver sections from untreated and atorvastatin-treated TO mouse. Results of
representative experiment of liver specimens incubated in vitro at 37°C with and without 1.0 μM atorvastatin for 6 hr is shown. A liver specimen
at 0 hr is also shown. Liver structure and cytology are preserved in treated and untreated specimens. Inflammation and cholestasis are absent.
(Hematoxylin and eosin, 10× and 40×).
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15 min following cortical surgery [29]. The in vitro levels
of ATP shown in Figure 1D, however, are much higher
than those reported for cultured rat hepatocytes at the
steady state level (2.44 ± 0.09 pmol mg-1) [25].
Urea synthesis is a sensitive biomarker for hepatocellular
functions. As shown in Table 1, the presence of atorvastatin
for up to 6 hr had no significant effect on the rate of hep-
atocyte urea synthesis. Consistently, hepatocyte structure
was preserved in the presence of atorvastatin (Figure 3).
Statins inhibit the rate-limiting step of cholesterol biosyn-
thesis catalyzed by HMG-CoA reductase. This inhibition
leads to decreased hepatic cholesterol synthesis, up-regula-
tion of low-density lipoprotein (LDL) receptor, and increased
clearance of plasma LDL-cholesterol. As a result of inhibiting
HMG-CoA reductase, statins could also inhibit the synthesis
of important isoprenoids, such as farnesylpyrophosphate
(FPP) and geranylgeranylpyrophosphate (GGPP). These in-
termediates serve as lipid attachments for the post-transla-
tional modification of intracellular proteins, such as nuclear
lamins, Ras, Rho, Rac and Rap [30]. Hence, the pleiotropic
effects of statins may arise from combined cholesterol
lowering effects and inhibition of intracellular isoprenoid-
dependent proteins.
Conclusion
In conclusion, this in vitro study shows that murine hep-
atocyte bioenergetics, caspase activity and histology are
preserved in the presence of high concentrations of ator-
vastatin for at least 6 hours. These observations are con-
sistent with the fact that long term atorvastatin therapy
is well tolerated clinically [8-10].
In pre-clinical drug development, in vitro studies are
routinely performed prior to in vivo testing. Due to poten-
tial pharmacodynamic differences, in vitro pharmaco-
logical studies should be followed by in vivo testing. The
biomarkers (hepatocyte bioenergetics and caspase activity)
described in this study, however, can be easily adapted for
in vivo studies. Moreover, due to potential species differ-
ences in response to atorvastatin, liver tissue from small
and large animals (e.g., rats and monkeys) are needed for
better prediction of organ toxicity.
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